National Multicenter Interventional Study Aimed at Evaluating the Effect on the Intestinal Microbiota in Chronically Frail Patients Who Share Alterations in Intestinal Function.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institute of Biomedical Technologies-National Research Council, Italy
With
Fondazione Serena Onlus - Centro Clinico NeMO Milano
IRCCS Eugenio Medea
Istituto Nazionale di Ricovero e Cura per Anziani
Clinical survey conducted for research and study purposes, multicenter, focusing on ALS patients, elderly patients with chronic diseases, and pediatric patients with neurodevelopmental disorders. For each of the diseases treated, patients will be randomized into the two treatment arms (Study Group, GS; Control Group, GC) according to a block randomization, with a block size of 4 and an allocation ratio of 1:1. The randomization will be double-blind.
* Study Group or GS: These subjects will be given an active symbiotic preparation consisting of two sticks of 1500mg each and of different colors.
* Control group or GC:These subjects will be given a passive symbiotic preparation again consisting of two sticks of 1500mg each.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Population 1 : ALS
Age at enrollment ≥18 years;
ALS diagnosis defined or probable according to El Escorial criteria (Brooks et al., 2000);
Respiratory function with FVC% \>50%.
children between 6 and 16 years old
children with ADHD, diagnosed with DSM-5 criteria and in accordance with the protocol shared by the Regional ADHD Reference Centers Lombardy.
adults above 18 years of age
diagnosed with Bronchial Ashtma following ERS-ETS criteria
You may not be if
Subjects unable to give informed consent to the study;
presence of psychiatric disease or severe cognitive impairment;
presence of tracheotomy; presence of severe pre-existing gastrointestinal disease (e.g., ulcerative rectocolitis; Crohn's disease).
Population 2: ADHD
presence of intellectual disability (QIT\<70),
presence of neurological diseases, epilepsy
presence of genetic syndromes
treatment with drug therapies.
Co-diagnosis with other psychiatric or neurodevelopmental disorders (i.e. Autism, Anxiety, Depression etc) will not be considered a criterion of exclusion.
Population 3: Bronchial Ashtma
life expectancy less than 18 months
active respiratory infections
cognitive disorders that prevent participation to the study (MMS \<24)